Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Most severe asthma patients don't need biologics long-term. A large UK study found that 70% of adults eligible for biologic therapy saw their exacerbations drop significantly with standard care alone. However, about 20% continued to have frequent flare-ups — and elevated blood eosinophil counts may be the key to spotting them early.
Most severe asthma patients improve without biologics — but a high-risk subset doesn't
A large retrospective study of over 10,000 UK adults with severe asthma found that the majority don't need long-term biologic therapy. Published in CHEST, the research tracked patients who were eligible for biologics (defined as having ≥3 exacerbations requiring oral corticosteroids in 12 months) for up to 7 years — and found three distinct trajectories.
The good news: 70% of patients fell into a "remitting-stable" group, with exacerbations dropping from a median of 4 to just 1 per year within the first 12 months and staying low. But roughly 30% didn't fare as well — 20% had persistently frequent flare-ups (median 5/year), and 10% had an extremely high burden (median >10/year).
By the Numbers:
Why it matters: These findings could reshape how clinicians approach biologic prescribing. Patients in the remitting-stable group may only need time-limited biologic therapy, while those with chronic-frequent exacerbations — flagged by persistent eosinophilia — may benefit from earlier intervention, even before hitting current eligibility thresholds. Better biomarkers are still needed to identify this high-risk group sooner.
